Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionexus Gene Lab Corp. (BGLC) on October 12, 2023. The company is incorporated in Wyoming and trades on the Nasdaq Capital Market. The report discloses a significant corporate governance event: the appointment of a new Chief Executive Officer and Director.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figure disclosed relates to executive compensation:
- CEO Annual Compensation: $24,000 (as per the employment agreement dated October 12, 2023).
Material Changes
The primary material change reported is the appointment of Mr. Chi Yuen Leong as Chief Executive Officer and a member of the Board of Directors, effective October 12, 2023. Mr. Leong previously served as the Company's President and director from its inception until August 2022.
Management Commentary and Risks
Management Commentary: The Board highlighted Mr. Leong's extensive experience in management, commercialization, finance, and the biotechnology industry. He holds a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia, and previously served as CEO of US Arem Pacific Corporation from 2009 to 2015. He played a key role in guiding the Company's listing on OTC and Nasdaq.
Risks and Contingencies: The filing states that Mr. Leong has no family relationship with other directors or officers and was not involved in any transactions requiring disclosure under Item 404(a) of Regulation S-K in the past two years. No other specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the effective date of Mr. Leong's appointment (October 12, 2023).
- Confirm the terms of the employment agreement, specifically the $24,000 annual compensation.
- Review Mr. Leong's prior tenure with the company (President/Director until August 2022) to understand the continuity of leadership.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.